Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 14/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | DRD4 | P21917 | 5/20 | 0.44 |
| ▸ | DRD3 | P35462 | 5/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.43 |
| ▸ | DRD5 | P21918 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1246333 | 0.98 | ADRB2 (0.51) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL245512 | 0.85 | ADRB2 (0.53) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL12119031 | 0.81 | ADRB2 (0.59) | ADRB2ADRB1DRD2DRD4DRD3 | |
| Tyramine SCHEMBL10640694 | 0.81 | ADRB2 (0.50) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL21517470 | 0.80 | ADRB2 (0.61) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL4727443 | 0.78 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL7281232 | 0.77 | HTR2A (0.50) | ADRB2DRD2DRD4DRD3DRD1 | |
| SCHEMBL10641652 | 0.77 | ADRB2 (0.52) | ADRB2ADRB1DRD2DRD4DRD3 | |
| SCHEMBL11379691 | 0.77 | DRD2 (0.56) | ADRB2ADRB1DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL10643506 | 0.76 | ADRB2 (0.51) | ADRB2ADRB1DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0125052-B1 | DOPAMINERGIC CARBOSTYRILS AND A PROCESS FOR PREPARING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-27 | — | — | EP | claimed |
| EP-0125052-A2 | Dopaminergic carbostyrils and a process for preparing them | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-14 | — | — | EP | claimed |
| EP-4219485-A1 | FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-02 | — | — | EP | disclosed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018011090-A1 | HYDROXYQUINOLINONE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017063564-A1 | OCTAHYDROCYCLOPENTA[C]PYRROLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE | 四川海思科制药有限公司 | 2017-04-20 | — | — | WO | disclosed |
| US-20120142646-A1 | Novel Compounds 621 | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| EP-2094646-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | AstraZeneca AB (SE) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008075025-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| EP-0125052-B1 | DOPAMINERGIC CARBOSTYRILS AND A PROCESS FOR PREPARING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1988-01-27 | — | — | EP | disclosed |
| EP-0125052-A2 | Dopaminergic carbostyrils and a process for preparing them | SMITHKLINE BECKMAN CORPORATION (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142646-A1 | Novel Compounds 621 | AR, ADRA1D, ADRA1B | ADRB2 18/4885ADRB1 4/4885DRD2 23/4885 |
| US-20100056508-A1 | AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885DRD2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.